Cyclosporine, an immunosuppressant with low toxicity, was found originally by a group of Swiss scientists in 1976. It had subsequently proven itself important in the survival of heart transplant patients. When newspaper advertising executive Mary Gohlke came to Stanford for her heart-lung transplant, however, the FDA had not yet approved cyclosporine for anything other than heart transplant. And it was processing applications facility by facility. After waiting for months for the approval, Gohlke asked the executive editor of her newspaper to see what he could do. He made calls, one of them to Arizona's U.S. senator. Shortly thereafter, Reitz got a call. Not only had the FDA approved Stanford's use of cyclosporine, it had given blanket approval to all qualified medical facilities to use the drug in heart-lung transplant. Gohlke's perseverance had opened the door for many others waiting for that approval.